Deep Origin explores combining AI and physics to improve virtual screening in drug discovery

Deep Origin has developed a hybrid virtual screening tool that combines generative AI with physics-based molecular modelling to improve prediction accuracy for novel biological drug targets, showing significantly higher hit rates in prospective wet-lab validations compared to traditional methods.

This Wire brief sits within Fusion42's coverage of Drug Discovery, Generative AI and Biotech.